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Summary Following up-regulation of an angiogenesis inhibitor by the wild-type p53 protein proven recently, we have analysed on the one
hand the prognostic impact of microvessel count (MC) and p53 protein overexpression in non-small-cell lung carcinoma (NSCLC) progression
and, on the other hand, the inter-relation between the microvascular pattern and the p53 protein expression. Moreover, we assessed the
expression of vascular endothelial growth factor (VEGF), one of the pivotal mediators of tumour angiogenesis, in order to investigate its
relation to p53 protein expression and MC. Tumours from 73 patients resected for NSCLC between March 1991 and April 1992 (median
follow-up 47 months, range 32-51 months) were analysed using an immunohistochemical method. In univaiiate analysis, MC and p53
accumulation were shown to affect metastatic nodal involvement, recurrence and death significantly. Multiple logistic regression analysis
showed an important prognostic influence of MC and nodal status on overall (P = 0.0009; P = 0.01) and disease-free survival (P = 0.0001;
P = 0.03). Interestingly, a strong statistical association was observed between p53 nuclear accumulation and MC (P = 0.0003). The same
inter-relationship was found in non-squamous histotype (P= 0.002). When we analysed the concomitant influence of MC and p53 expression
on overall survival, we were able to confirm a real predominant role of MC in comparison with p53. With regard to VEGF expression, p53-
negative and lowly vascularized tumours showed a mean VEGF expression significantly lower than p53-positive and highly vascularized
cancers (P = 0.02). These results underline the prognostic impact of MC and p53 protein accumulation in NSCLC and their reciprocal inter-
relationship, supporting the hypothesis of a wild-type p53 regulation on the angiogenetic process through a VEGF up-regulation.
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The most important steps in the evaluation of human cancers
include diagnosis and prognosis. Prognostic evaluation represents
a critical step involving a therapeutic approach. In the last two
decades, major efforts have been directed towards a biological
characterization of human solid cancers, and interesting results
have been obtained in this field (Harris and Hollstein, 1993).
Some biological parameters have been shown to have an impor-
tant role in both the development and the progression of several
types of human cancer. Non-small-cell lung carcinoma is a lung
cancer subgroup ofparticular interest forits heterogeneity in terms
of both histopathological classification and behaviour. Up until
now, NSCLC prognosis has been strongly influenced by clinico-
pathological parameters (i.e. performance status, tumour status,
nodal metastatic involvement and distant metastasis), although
several recent studies have demonstrated aputative prognostic role
ofbiological factors for this group of cancers (Slebos et al, 1991;
Tateishi et al, 1991; Fontanini et al, 1992). In particular, some
protein products, such as p53 protein, are directly involved in
the cancerization mechanism, malignant transformation and
progression, and the angiogenetic pattern with regard to the
number ofmicrovessels has been shown to influence considerably
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the prediction of recurrence and death in these types of cancer
(Quinlan et al, 1992; Macchiarini et al, 1992).
Recent experimental evidence in cultured fibroblasts from
Li-Fraumeni patients has underlined thatthe switch totheangiogenic
phenotype coincides with loss of the wild-type p53 tumour-
suppressor gene with consequent reduced expression ofsome angio-
genic inhibitors, such as thrombospondin-l (Dameron et al, 1994).
Since tissue p53 protein expression results from gene alter-
ations, we analysed on the one hand the prognostic influence of
p53 accumulation and microvessel count in a series of NSCLCs
and on the other hand their mutual relation as a basis for studying
the putative regulation of angiogenesis by the p53 gene in the
epithelial tissue as well.
The supposed induction of the VEGF expression through the
proteinkinaseCpathway stimulation in the presence ofp53 tumour-
suppressor gene mutation (Kieser et al, 1994) also prompted us to
analyse the VEGFpattern in an attempt to identify apotential mech-
anism ofthe angiogenesis regulation by tumour-suppressor genes in
solid cancers.
MATERIALS AND METHODS
Patients
Seventy-three patients resected for non-small-cell lung cancer at
the Santa Chiara Hospital of Pisa University from March 1991 to
April 1992 were studied. Patients (66 men and seven women
with a mean age of 63 years) had a clinical follow-up ranging
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Figure 1 p53 protein accumulation in the nuclei of neoplastic cells in a
NSCLC sample (ABC method; 25 x)
Table 1 Clinicopathological characteristics of 73 cases of NSCLC according
to p53 protein expression and MC
p53 MC
Variables No. of Mean + s.d. P Mean ± s.d. P
cases
Sex
Male 66 30.2 +28 22.1 ±14
NS NS
Female 7 30.1 +38 24.5 ±14
Histology
Squamous 45 27.7 ±27 19.2 + 12
NS NS
Non-squamous 28 34.3 ± 31 27.4 + 14
T status
Ti 15 26.5 +32 16.9 ±13
T2 49 30.6 ±27 NS 22.5 ±14 NS
T3 9 32.1 ±36 28.6 ±13
N status
NO 51 25.8 ±27 19.2 ±12
0.04 0.002
N1-2 22 40.5 +30 29.8 +13
Stage
S1 46 24.9 ±27 18.6 ±12
0.04 0.002
S1-2 27 39.2 ±29 28.8 ±14
from 32 to 51 months (average 47 months). Tumour staging was
performed according to the TNM staging system (Mountain, 1986)
and the World Health Organization Histological Classification
(World Health Organization, 1982).
Immunohistochemical procedures
p53protein expression
The p53 protein expression was assessed in frozen tissue samples
using immunohistochemistry. PAb1801 (Oncogene Science,
Manhasset, NY, USA) is a monoclonal antibody that recognizes an
epitope in p53 protein between amino acids 32 and 79. The
avidin-biotin peroxidase method was used developing immuno-
reaction with diaminobenzidine. Simultaneous staining ofaknown
p53-positive case was used as a positive control for p53.
Incubation of parallel slides omitting the first antibody was
performed as a negative control. The count ofp53-immunoreactive
cells was made by scoring a minimum of five high-power fields
(HPFs) (40 x objective lens) and counting in each field the number
ofimmunoreactive cells on the total ofneoplastic cells. We consid-
ered p53 immunostaining as both a continuous and a dichotomous
variable assuming the median value of20% ofpositive cells as cut-
offto distinguish low from high p53-expressing tumours.
Microvascular count
MC was determined on methacarn-fixed and paraffin-embedded
tumour samples at the time of resection, using the anti-FVIII
monoclonal antibody diluted 1:50 overnight, displayed by the
ABC method. Anti-FVIII MAb labels the vascular endothelium
and provides easy identification of the most intense areas of
neovascularization in the tumours. A single microvessel was
defined as any brown immunostained endothelial cell separated
from adjacent microvessels, tumour cells and other connective
tissue elements (Figure 3). Each sample was examined at low
power (10 x objective lens and 10 x ocular lens) to identify the
area with the highest number of microvessels. The microvessels
were then carefully counted in this area on a 250 x field (25 x
objective lens and 10 x ocular lens, 0.78 mm2 per field). We
considered MC as both continuous and dichotomous variable
assuming the median value of 15 vessels as cut-offvalue to distin-
guish low from high MC.
Vascular endothelialgrowth factorexpression
Staining for VEGF was performed on 66 out of the entire series
(90.4%) using a polyclonal anti-VEGF antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at a 1:50 of dilution
overnight. As for the otherimmunostainings, immunoreaction was
displayed using the avidin-biotin peroxidase complex method.
The peroxidase activity was visualized with diaminobenzidine.
Counterstaining was performed with haematoxylin. Negative
controls were carried out by omitting the primary antibody. The
VEGF expression was assessed according to the percentage of
immunoreactive cells on a total of at least 1000 neoplastic cells.
We considered as negative the samples with no immunoreactive
cells in their neoplastic component.
Statistical analyses
All statistical analyses were carried out by the Statistica (Stat-Soft)
software system. A chi-square test with Fisher's correction was
used to analyse the associations between different variables. The
differences between the mean of MC and p53 in patients with or
without metastasis and alive or dead were assessed by the unpaired
t-test as well as VEGFexpression incomparison withp53-negative
vs p53-positive or low-vascularized vs high-vascularized tumours.
The survival analyses were calculated by the Kaplan-Meier
method. The differences between tumours with low or high MC
and p53 protein were evaluated by the log-rank test.
RESULTS
The most common histological type was squamous carcinoma
(61.6%). Out of 73 tumours 45 (67.1%) were classified as T2
(more than 3 cm in the greatest dimension or invading visceral
pleura); 22 out of73 (30.1%) presented metastatic involvement of
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Table 2 p53 protein expression and MC of 73 cases of NSCLC according to
recurrence and overall survival
p53 MC
Variables No. of Mean ±s.d. P Mean +s.d. P
cases
Recurrence
No 40 23.5 27 15.2 9
0.02 0.0001
Yes 33 38.4 29 31.1 14
Overall survival
Alive 44 23.8 26 15.7 8
0.01 0.0001
Dead 29 39.9 30 32.5 14
Figure 3 Tumour area with high microvascular count in an invasive NSCLC
sample (ABC method; 25 x)
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Figure 2 Relapse-free (A) and overall survival (B) in NSCLC patients
according to high (> 20) and low (< 20) p53 protein expression
hilar and/or mediastinal lymph nodes and 32 patients developed
distant metastases during follow-up. A total of29 (39.7%) patients
died of metastatic disease, while 44 were alive at the moment of
analysis.
p53 expression
p53 immunoreactivity was localized in the nuclei of neoplastic
cells (Figure 1). The median value (20% of positive cells) was
assumed as the cut-off value to distinguish tumours with low or
high p53 expression. Tables 1 and 2 report the mean values ofp53
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Figure 4 Relapse-free (A) and overall survival (B) of NSCLC patients
according to high (> 15) and low (< 15) MC
protein according to the clinicopathological characteristics and
behaviour of the tumours. A higher p53 expression was shown to
be associated with late-staged (N1-2; S2-3) and recurring carci-
nomas (P = 0.04; P = 0.02). Moreover, patients with high (> 20%
of positive cells) p53-expressing tumours showed a significantly
shorter relapse-free and overall survival than those with a low
(< 20% ofpositive cells) p53 accumulation in theircancers (Figure
2A: P = 0.006; Figure 2B: P = 0.01).
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Table 3 Multiple logistic regression to predict overall survival in NSCLC
Coefficent Standard
Variables b b error t P
Age 0.1617 0.1018 1.5875 0.1172
Sex 0.0643 0.1059 0.6038 0.5480
Histotype 0.1081 0.1087 0.9943 0.3237
N status 0.2840 0.1101 2.5789 0.0121
Microvessel count 0.3776 0.1085 3.4777 0.0009
p53 0.1141 0.1068 1.0684 0.2892
Table 4 Multiple logistic regression to predict recurrence in NSCLC
Coefficent Standard
Variables b b error t P
Age 0.0892 0.1020 0.8748 0.3848
Sex 0.0089 0.1067 0.8397 0.9333
Histotype 0.0517 0.1089 0.4751 0.6362
N status 0.2422 0.1103 2.1960 0.0316
Microvessel count 0.4336 0.1087 3.9863 0.0001
p53 0.1105 0.1069 1.0336 0.3051
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Figure 6 Relation between MC and p53 protein expression in 73 cases of
NSCLC (linear regression r= 0.41; P= 0.0003)
Table 5 Relationship between MC and p53 protein expression in NSCLC
p53
Variables No. of cases Mean ± s.d. P
Microvessel count
Low 37 19.7 22
0.001
High 36 41.1 31
All cases except
MC>15 and p53>20
60
0
40
P=0.001
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Figure 5 Overall survival of NSCLC patients according to high MC and high
p53 and all cases except high MC and high p53
r= 0.57; P= 0.001
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Microvascular count
The area of most intense vascular count was identified for each
tumour sample (Figure 3) and the median value of this series (15
vessels per 250 x power field) allowed us to separate tumours with
high from tumours with low MC. Tables 1 and 2 show that tumours
with metastatic nodal involvement and/or which relapsed during
follow-up had a higher number of microvessels compared with
cancers with no metastatic involvement (P = 0.002; P = 0.0001). In
addition, shorter relapse-free and overall survival were observed in
patients with high microvessel count in their tumours (Figure 4A:
P = 0.00003; Figure 4B: P = 0.00001). Multiple logistic regression
analyses reported in Tables 3 and 4 underlined the strong prog-
nostic influence ofMC and nodal status on overall (P = 0.0009; P =
0.01) and relapse-free survival (P = 0.0001; P = 0.03). The prog-
nostic impact of MC was further confirmed when we analysed the
concurrent influence ofMC andp53 expression onoverall survival.
As reported in Figure 5, a significant statistical difference in overall
survival was observed between patients whose tumours showed
alternatively low MC and low p53, low MC andhigh p53, high MC
p53
Figure 7 Relation between MC and p53 protein in 28 cases of non-
squamous subgroup of NSCLC (linear regression r= 0.58; P= 0.001)
and low p53 (condensed below 'All cases except MC > 15p53 >
20') compared with patients whose tumours showed both high
MC and high p53 (P = 0.001).
Relation between p53 expression and microvessel
count
Interestingly, when MC was compared with p53 nuclear accumu-
lation, a strong statistical association was found between these two
variables (linear regression: r = 0.41; P = 0.0003) (Figure 6). In
fact, mean p53 immunoreactivity was significantly more intense
(41.1 ± 31) in tumours with high MC than in those with low MC
(19.7 ± 22) (P = 0.01), as reported in Table 5. Given the fact that
the non-squamous histotype had a higher MC than squamous cell
carcinomas, it was interesting to check any correlation between
MC and p53 positivity even in the case of histological types. A
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Table 6 VEGF expression according to MC and p53
VEGF
Variables No. of cases Mean ± s.d. P
MC
Low 34 29 22
0.02
High 32 42.3 22
p53
Negative 20 25.6 21
0.02
Positive 46 39.7 23
p53
Low 25 28 20
0.04
High 41 40 24
strong statistical association was foundbetweenp53 andMC in non-
squamous subtypes as reported in Figure 7 (r = 0.58; P = 0.001).
VEGF expression according to MC and p53
VEGF immunoreactivity was detected in the cytoplasm of
neoplastic cells with particular accumulation in the perinuclear
area (Figure 8) and 63 out of66 ofthe tumours (95.4%) expressed
VEGF protein (mean 37.1 + 22; range 5-80%). The median value
(40) ofthe whole series was assumed as the cut-offvalue to distin-
guish tumours with low from tumours with high VEGF expres-
sion. A significant statistical association was found between
VEGF expression and both MC and p53 immunoreactivity. As
shown in Table 6, the p53-positive and highly vascularized
tumours (MC > 15 vessels per 250 x field) showed a significantly
higher VEGF protein expression (P = 0.02; P = 0.02). The same
statistical association was maintained comparing VEGF expres-
sion in tumours with low or high p53 according to the median
value ofp53 (< vs > 20% ofpositive cells) (P = 0.04) (Table 6).
DISCUSSION
In this study, we took into account the role ofMC and p53 protein
expression in the progression of one of the most frequent and
aggressive types of epithelial human cancer, non-small-cell lung
carcinoma. Our results have focused on two main aspects: the
prognostic impact ofMC and p53 expression and the inter-relation
between these two factors.
MC and prognosis
The prognostic role ofMC has been widely reported in several types
of solid human cancer, such as mammary (Weidner et al, 1991),
head andneck (Gasparini etal, 1993), prostate (Weidneretal, 1993),
ovarian (Hollingsworth et al, 1995), colorectal (Saclarides et al,
1994), testicular (Olivarez etal, 1994), urotelial (Uaegeretal, 1994),
cutaneous (Barnhill et al, 1992), nervous (Li et al, 1994) and
bronchial carcinomas (Macchiarini et al, 1992; Yamasaki et al,
1994; Fontanini et al, 1995a). These studies, mostly in breast
cancers, have shown that intra-tumour microvessel count has an
independent prognostic significance when compared with tradi-
tional prognostic markers in multivariate analysis (Gasparini and
Figure 8 Cytoplasmic VEGF expression in well-differentiated
adenocarcinoma of the lung (ABC method; 25 x)
Harris, 1995). In our study, an increasing intra-tumour microvessel
count with greater incidence of metastases and/or decreased patient
survival has been observed, confirmingboth ours and otherprevious
data in lung cancer and in other types of solid neoplasms
(Macchiarini et al, 1992; Yamasaki et al, 1994; Fontanini et al,
1995b; Weidner and Folkman, 1996).
The formation of new capillaries makes it possible for the
tumour cells to gain secondary sites successfully and to develop
metastases. For this reason, the microvascular bed represents an
important requirement for the growth and metastatic spread of
primary tumours and also the biological foundation of the prog-
nostic potential ofMC.
p53 expression and prognosis
Alterations of the p53 gene with consequent nuclear overexpres-
sion have been observed in several human cancers, including
NSCLC (Lane, 1990), underlining the important role ofp53 modi-
fications in tumour development. These alterations seem to be an
early eventduring bronchial cancerprogression as demonstratedby
several authors who have reported a p53 accumulation in preinva-
sive lesions of the bronchial tree (Sozzi et al, 1992; Sundaresan et
al, 1992; Bennett etal, 1993; Fontanini et al, 1994). However, some
experimental evidence has also shown an association between
shorter survival and p53 protein expression (Quinlan et al, 1992;
Fontanini et al, 1995a), although further information will obviously
be necessary before this parameter can be used in the prognostic
evaluation of human cancers. Indeed, the putative prognostic role
ofthe p53 also observed in this series contrasts with recent results
by Lee et al (1995), who report a favourable prognostic influence
of p53 expression in a series of 156 resected primary NSCLCs.
However, there are substantial differences between ours and Lee et
al's methods. As a matter offact, we observed a lower median p53
valuecompared with the median value observedby Lee etal (1995)
in the histotypes they analysed. The different number of positive
cells in their tumours may be caused by the different immunohisto-
chemical procedures, which used microwave oven techniques in
formalin-fixed and paraffin-embedded tumour samples, with
consequently more consistent staining for the p53 protein.
Moreover, the favourable prognostic influence of the p53 overex-
pression was observed by Lee's group in a subset ofNSCLCs with
arestricted vision ofthep53 prognostic significance. The influence
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ofthe high p53 expression on the outcome ofthis series ofNSCLC
patients apparently disagrees with the early expression of the
protein during NSCLC development. The early appearance ofp53
accumulation is likely to confer to initiated cells a more aggressive
phenotype resulting in a faster progression of p53-positive
tumours. Thus, the detection of the altered p53 expression may
provide prognostic information about the clinical behaviour of
primary NSCLC.
p53 expression and MC
In our study, p53 tumour expression and MC were compared for
the analysis of their reciprocal inter-relation. Tumours with high
MC both in the entire series and in the non-squamous subgroup
presented an increasing p53 expression, suggesting a putative
influence of this tumour-suppressor gene on the development of
the angiogenic pattern. Recent experimental evidence suggests
that new vessel formation in tumours as well as in cultured cell
lines is under tumour-suppressor gene control. In a cultured BHK
fibroblast cell line converted to anchorage independence and
tumorigenicity by loss of a tumour-suppressor gene, Rastinejed et
al (1989) have shown that suppressor loss is accompanied by a
gain in their ability to acquire the angiogenic phenotype.
Moreover, in a glioblastoma cell line that does not express the p53
protein because of an internal rearrangement of the gene and that
causes tumours with glioblastoma histology, Van Meier et al
(1994) have underlined a down-regulation of angiogenetic capa-
bility following introduction of a tetracycline-regulated wild-type
p53 gene into the cells. Concomitantly, in the fibroblast ofpatients
with Li-Fraumeni syndrome, Dameron et al (1995) have demon-
strated that the loss of the wild-type p53 is followed by a down-
regulation ofa potent inhibitor ofangiogenesis.
MC, p53 and VEGF expression
This is the first study in which the relation between MC, p53 and
VEGF expressions has been investigated in human lung carci-
noma. Recently, Mattern et al (1996) analysed a series of 91
epidermoid lung carcinomas and, apart from the different
percentage of cancers expressing the VEGF protein, they found a
statistical association between the MC and VEGF expression.
They did not analyse the relation between p53 and VEGF, which
appears to be strictly connected in the regulation oftumour angio-
genesis. Recently, some data have been achieved concerning the
influence of wild-type p53 on the human VEGF expression by
Mukhopadhyay et al (1995), who demonstrated a pronounced
suppressive effect ofthe VEGF gene expression on an adenovirus-
transformed human fetal kidney cell line. On the other hand, a
mutant form ofp53 has been shown to be implicated in the 12-0-
tetradecanoylphorbol- 13-acetate induction of the VEGF gene
expression mediated by the protein kinase C (Kieser et al, 1994).
The association between VEGF, MC and p53 underlines on the
one hand the important role of VEGF in the control of neoangio-
genesis in NSCLC, and on the other hand the hypothesis that the
wild-type p53 protein may stop cell cancer development by
attracting newly formed vessels.
On the basis ofthe in vitro and in vivo evidence, we believe that
a more detailed analysis ofangiogenic growth factors and inhibitor
expression in human tumour samples will provide useful informa-
tion about the genetic control of the angiogenic phenomenon in
cancer.
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MC, microvessel count; VEGF, vascular endothelial growth
factor; NSCLC, non-small-cell lung cancer; OS, overall survival;
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